Lipids

Pneumocystis Pneumonia: Third Edition, Revised and Expanded

Volumn , Issue , 2004, Pages 539-576

  Kaneshiro, Edna S ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33751353009     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (116)

1. Kaneshiro ES. The lipids of Pneumocystis carinii. Clin Microbiol Rev 1998; 11: 27-41.
2. Kaneshiro ES. Pneumocystis carinii pneumonia: the status of Pneumocystis biochemistry. Int J Parasitol 1998; 28:65-84.
3. Stringer JR, Cushion MT, Wakefield AE. New nomenclature for the genus Pneumocystis. J Eukaryot Microbiol 2001; 48:184S-189S.
4. Frenkel JK. Pneumocystis jiroveci n. sp. from man: morphology, physiology, and immunology in relation to pathology. Natl Cancer Inst Monogr 1976; 43:13-30.
5. Sloand E, Laughon B, Armstrong M, Bartlett MS, Blumenfeld W, Cushion M, Kalica A, Kovacs JA, Martin W, Pitt E, Pesanti EL, Richards F, Rose R, Walzer P. The challenge of Pneumocystis carinii culture. J Eukaryot Microbiol 1993; 40: 188-195.
6. Merali S, Frevert U, Williams JH, Chin K, Bryan R, Clarkson AB. Continuous axenic cultivation of Pneumocystis carinii. Proc Natl Acad Sci USA 1999; 96: 2402-2407.
7. Harwood JL. Lung surfactant. Prog Lipid Res 1987; 26:211-256.
8. Sheehan PM, Stokes DC, Yeh Y-Y, Hughes WT. Surfactant phospholipids and lavage phospholipase A2 in experimental Pneumocystis carinii pneumonia. Am Rev Respir Dis 1986; 134:526-531.
9. Kaneshiro ES, Wyder MA, Zhou LH, Ellis JE, Voelker DR, Langreth SG. Characterization of Pneumocystis carinii preparations developed for lipid analysis. J Eukaryot Microbiol 1993; 40:805-815.
10. Boylan CJ, Current WL. Improved model of Pneumocystis carinii pneumonia: induced laboratory infection in Pneumocystis-free animals. Infect Immun 1992; 60: 1589-1597.
11. Cantin AM, North SL, Hubbard RL, Crystal RG. Normal alveolar epithlia fluid contains high levels of glutathione. J Appl Physiol 1987; 63:152-157.
12. Basselin M, Lipscomb KJ, Qiu YH, Kaneshiro ES. Transport of aspartic acid, tyrosine, and arginine by the opportunistic protist Pneumocystis carinii. Biochim Biophys Acta 2001; 1511:349-359.
13. Kaneshiro ES, Wu Y-P, Cushion MT. Assays for testing Pneumocystis carinii viability. J Protozool 1991; 38:85S-87S.
14. Kaneshiro ES, Wyder MA, Wu Y-P, Cushion MT. Reliability of calcein methoxy methyl ester and ethidium homodimer or propidium iodide for viability assessment of microbes. J Microbiol Methods 1993; 17:1-16.
15. 32 sterols in Pneumocystis carinii hominis-infected human lungs. J Eukaryot Microbiol 1996; 43:36S.
16. Paulsrud JR, Queener SF. Metabolism of fatty acids and amino acids by cultured Pneumocystis carinii. J Eukaryot Microbiol 1994; 41:633-638.
17. Kaneshiro ES, Sleight RG. Biochemistry and metabolism. In Walzer PD, Ed. Pneumocystis carinii Pneumonia. 2d ed. New York: Marcel Dekker, 1994:45-71.
18. Furlong ST, Koziel H, Bartlett MS, McLaughlin GL, Shaw MM, Jack RM. Lipid transfer from human epithelial cells to Pneumocystis carinii in vitro. J Infect Dis 1997; 175:661-668.
19. Florin-Christensen M, Florin-Christensen J, Kaneshiro ES. Uptake and metabolism of L-serine by Pneumocystis carinii carinii. J Eukaryot Microbiol 1995; 42: 669-675.
20. Basselin M, Qui YH, Lipscomb KJ, Kaneshiro ES. Uptake of the neutral amino acids glutamine, leucine and serine by Pneumocystis carinii. Arch Biochem Biophys 2001; 391:90-98.
21. Sleight RG, Mehta MA, Kaneshiro ES. Uptake and metabolism of fluorescent lipid analogs by Pneumocystis carinii. J Eukaryot Microbiol 1995; 41:111S.
22. Kaneshiro ES, Ellis JE, Guo Z, Jayasimhulu K, Maiorano JN, Kallam KA. Characterizations of neutral lipid fatty acids and cis-9,10-epoxy octadecanoic acid in Pneumocystis carinii carinii. Infect Immun 1996; 64:4105-4114.
23. 10 as the major ubiquinone homolog. J Eukaryot Microbiol 1996; 43:165-170.
24. Paulsrud JR, Glancy TP, Shaw MM, Bartlett MS, Smith JW. Fatty acid metabolism of Pneumocystis carinii in culture, 38th Annual Meetings of the American Society of Tropical Medicine and Hygiene, December 10-14, 1989, Honolulu, HI.
25. Paulsrud JF, Queener SF. Metabolism of fatty acids and amino acids by cultured Pneumocystis carinii in culture, 47th Annual Meeting, Society of Protozoologists, June 24-29, 1994, Cleveland, OH.
26. Sorice M, Lenti L, Misasi R, Contini C, Cignarella L, Griggi T, Vullo V, Masala C. Evidence for the existence of ganglioside molecules on Pneumocystis carinii from human lungs. Parasitology 1992; 105:1-6.
27. Pesanti EL. Phospholipid profile of Pneumocystis carinii and its interaction with alveolar type II epithelial cells. Infect Immun 1987; 55:736-741.
28. Guo Z, Kaneshiro ES. Phospholipid composition of Pneumocystis carinii carinii and effects of methylprednisolone immunosuppression on rat lung lipids. Infect Immun 1995; 63:1286-1290.
29. Pesanti EL, Cox C. Metabolic and synthetic activities of Pneumocystis carinii in vitro. Infect Immun 1981; 34:908-914.
30. Kaneshiro ES, Guo Z, Sul D, Kallam K, Jayasimhulu K, Beach DH. Characterizations of Pneumocystis carinii and rat lung lipids: glyceryl ethers and fatty alcohols. J Lipid Res 1998; 39:1907-1917.
31. Paulsrud JR, Queener SF, Bartlett MS, Smith JW. Total cellular fatty acid composition of cultured Pneumocystis carinii. J Clin Microbiol 1991; 31:1899-1902.
32. Yoshikawa H, Morioka H, Yoshida Y. Freeze-fracture localization of filipin-sterol complexes in plasma- and cyto-membranes of Pneumocystis carinii. J Protozool 1987; 34:131-137.
33. Yoshikawa H, Yoshida Y. Distribution of digitonin-sterol complexes in Pneumocystis carinii revealed by freeze-fracture method. Int J Parasitol 1988; 18:39-45.
34. Kaneshiro ES, Ellis JE, Jayasimhulu K, Beach DH. Evidence for the presence of ‘metabolic sterols’ in Pneumocystis: identification and initial characterization of Pneumocystis carinii sterols. J Eukaryot Microbiol 1994; 41:78-85.
35. Furlong ST, Samia JA, Rose RM, Fishman JA. Phytosterols are present in Pneumocystis carinii. Antimicrob Agents Chemother 1994; 38:2534-2540.
36. 24,(25) sterol methyltransferase block sterol synthesis and cell proliferation in Pneumocystis carinii. Antimicrob Agents Chemother 1997; 41:1428-1432.
37. Giner J, Zhao H, Beach DH, Parish EJ, Jayasimhulu K, Kaneshiro ES. Comprehensive and definitive structural identities of Pneumocystisi carinii sterols. J Lipid Res 2002; 43:1114-1124.
38. Kaneshiro ES. Lipid metabolism of Pneumocystis: toward the definition of new molecular targets. FEMS Immunol Med Microbiol 1998; 22:135-144.
39. Kaneshiro ES. Sterol biosynthesis in Pneumocystis: unique steps that define unique targets. Drug Resist Updates 2002; 257:1-10.
40. Haughan PA, Goad LJ. Lipid biochemistry of trypanosomatids. In Coombs GH, North MD, Eds. Biochemical Protozoology. London: Taylor & Frances, 1991: 312-328.
41. Vanhanen HT, Miettinen TA. Effects of unsaturated and saturated dietary plant sterols on their serum contents. Clin Chim Acta 1992; 205:97-107.
42. Yarbrough DN, Basseslin-Eiweida M, Kaneshiro ES. Can Pneumocystis methylate the C-24 position of sterols scavenged from the host? (abstr). J Eukaryot Microbiol 2003; 50:5A.
43. Florin-Christensen M, Florin-Christensen F, Wu Y-P, Zhou LH, Gupta A, Rudney H, Kaneshiro ES. Occurrence of specific sterols in Pneumocystis carinii. Biochem Biophys Res Commun 1994; 198:236-242.
44. Kaneshiro ES, Ellis JE, Zhou LH, Rudney H, Gupta A, Jayasimhulu K, Setchell KDR, Beach DH. Isoprenoid metabolism in Pneumocystis carinii. J Eukaryot Microbiol 1995; 41:93S.
45. Contini C, Manganaro M, Romani R, Tzatzoglou S, Poggesi I, Vullo V, Delia S, De Simone C. Activity of terbinafine against Pneumocystis carinii in vitro and its efficacy in the treatment of experimental pneumonia. J Antimicrob Agents Chemo-ther 1994; 34:727-735.
46. Kaneshiro ES, Collins M, Cushion MT. Inhibitors of sterol biosynthesis and amphotericin B reduce the viability of Pneumocystis carinii f. sp. carinii. Antimicrob Agents Chemother 2000; 44:1630-1638.
47. Cushion MT, Slaven BE, Arnold J, Wunderlich J, Staben C, Sesterhenn T, Smulian AG. Inferred metabolic capacity of Pneumocystis f. sp. carinii through genomics and informatics, 7th International Workshops on Opportunistic Protists, June 13-16, 2001, Cincinnati, OH.
48. Liendo A, Visbal G, Piras MM, Urbina JA. Sterol composition and biosynthesis in Trypanosoma cruzi amastigotes. Mol Biochem Parasitol 1999; 104:81-91.
49. Weete JD. Lipid Biochemistry of Fungi and Other Organisms. New York: Plenum Press, 1980.
50. Weete JD. Structure and function of sterols in fungi. Adv Lipid Res 1989; 23: 484-491.
51. Weete JD, Fuller MS, Huang MQ, Gandhi S. Fatty acids and sterols of selected hypochytriomycetes and chytridiomycetes. Exp Mycol 1989; 13:183-195.
52. 32 sterols in Pneumocystis, an opportunistic pathogen of immunocompromised mammals. Lipids 2000; 35:317-324.
53. Joubert BM, Matsuda SPT, Buckner FS. Cloning and characterization of oxidosqua-lene cyclases in trypanosomes and the parasitic fungus Pneumocystis carinii, 7th International Workshops on Opportunistic Protists, June 13-16, 2001, Cincinnati, OH.
54. Nes WD. Sterol methyl transferase: enzymology and inhibition. Biochim Biophys Acta 2000; 1529:63-88.
55. Akihisa T, Moto E, Shimizu N, Tamura T, Matsumoto T. 24-Methylenelanost-8-enol and (24E) - and (24Z)-24-ethylidenelanost-8-enols in Neolitsea sericea. J Jpn Oil Chem Soc 1986; 35:731-735.
56. Kaneshiro ES, Amit Z, Swonger MM, Kreishman GP, Brooks EE, Kreishman M, Jayasimhulu K, Parish EJ, Sun H, Kizito SA, Beach DH. Pneumocysterol [(24Z)-ethylidenelanost-8-en-3ß-ol], a rare sterol detected in the opportunistic pathogen Pneumocystis carinii f. sp. hominis: structural identity and chemical synthesis. Proc Natl Acad Sci USA 1999; 96:97-102.
57. Kaneshiro ES, Amit Z, Chandra J, Baughman RP, Contini C, Lundgren B. The sterol composition of Pneumocystis carinii hominis organisms isolated from human lungs. Clin Diagn Lab Immunol 1999; 6:970-976.
58. Amit Z. Analysis of Pneumocystis carinii Sterols from Various Mammalian Hosts, Including Humans. MS thesis, University of Cincinnati, Cincinnati, OH, 1998.
59. Amit Z, Kaneshiro ES. Heterogeneity of Pneumocystis sterol profiles in samples from different sites of the same lung suggests co-infection by distinct organism populations. J Clin Microbiol 2001; 39:1137-1139.
60. Qiu Y. Leucine Uptake and Incorporation into Pneumocystis carinii f. sp. carinii Sterols. MS thesis, University of Cincinnati, Cincinnati, OH, 2001.
61. Shapiro DJ, Rodwell VW. Regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase and cholesterol synthesis. J Biol Chem 1971; 246:3210-3216.
62. Sul D, Kaneshiro ES. Pneumocystis carinii f. sp. carinii biosynthesizes de novo four homologs of ubiquinone. J Eukaryot Microbiol 2001; 48:184-189.
63. Walzer PD, Ashbaugh A. Use of terbinafine in mouse and rat models of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 2002; 46:514-516.
64. Kaneshiro ES, Rosenfeld J, Basselin M, Stringer JR, Keely S, Smulian AG, Giner J-L. The Pneumocystis carinii drug target S-adenosyl-L-methionine:sterol methyl transferase has a unique substrate preference. Mol Microbiol 2002; 44:989-999.
65. Merali S, Vargas D, Franklin M, Clarkson AB. S-Adenosylmethionine and Pneumocystis carinii. J Biol Chem 2000; 275:14958-14963.
66. Beach DH, Chen F, Cushion MT, Macomber RS, Krudy GA, Wyder MA, Kaneshiro ES. Effects of steroidal allenic phosphonic acid derivatives on the parasitic protists Leishmania donovani, Leishmania mexicana mexicana and Pneumocystis carinii carinii. Antimicrob Agents Chemother 1997; 41:162-168.
67. Kaneshiro ES, Rosenfeld JA, Basselin M, Bradshaw S, Stringer JR, Smulian AG, Giner J-L. Pneumocystis carinii erg6 gene: sequencing and expression of recombinant SAM:sterol methyltransferase in heterologous systems. J Eukaryot Microbiol 2001; 48:144S-146S.
68. Barajas-Aceves M, Hassan M, Tinoco R, Vazquez-Duhalt R. Effect of pollutants on the ergosterol content as indicator of fungal biomass. J Microbiol Methods 2002; 50:227-236.
69. White DC, Lytle CA, Gan YD, Piceno YM, Wimpee MH, Peacock AD, Smith CA. Flash detection/identification of pathogens, bacterial spores and bioterrorism agent biomarkers from clinical and environmental matrices. J Microbiol Methods 2002; 48:139-147.
70. Amit Z, Wyder MA, Keely S, Baughman RP, Kaneshiro ES. Sterol recycling in the lung could explain the presence of Pneumocystis sterols in the absence of organisms in human bronchoalveolar lavage fluid (abstr). J Eukaryot Microbiol 2003; 50:5A.
71. Crane FL. Development of concepts for the role of ubiquinones in biological membranes. In Lenaz G, Barnabei O, Rabbi A, Battino M, Eds. Highlights in Ubiquinone Research. London: Taylor & Francis, 1990:3-17.
72. Crane FL, Sun IL, Sun EE. The essential functions of coenzyme Q. Clin Invest 1993; 71:S55-S59.
73. Ellis JE, Setchell KDR, Kaneshiro ES. Detection of ubiquinone in parasitic and free-living protozoa, including species devoid of mitochondria. Mol Biochem Para-sitol 1994; 65:213-224.
74. Barr R, Branstetter BA, Rajnicek A, Crane FL, Low H. Chloroquine-sensitive transplasmalemma electron transport in Tetrahymena pyriformis: a hypothesis for control of parasite protozoa through transmembrane redox. Biochim Biophys Acta 1991; 1058:261-268.
75. Datta G, Bera T. Transplasma membrane electron transport in Leishmania donovani promastigotes. J Eukaryot Microbiol 2002; 49:24-29.
76. Ellis JE. Coenzyme Q homologs in parasitic protozoa as targets for chemotherapeutic attack. Parasitol Today 1994; 10:296-301.
77. + ATPases. J Eukaryot Microbiol 1995; 42:298-307.
78. + -ATPase regulates cytoplasmic pH in Pneumocystis carinii trophozoites. Biochem J 1996; 316:681-684.
79. VanderHeyden N, McLaughlin GL, Docampo R. Regulation of the plasma membrane potential in Pneumocystis carinii. FEMS Microbiol Lett 2000; 183:327-330.
80. Basselin-Eiweida M, Kaneshiro ES. Detection of two distinct transporter systems for 2-deoxyglucose uptake by the opportunistic pathogen Pneumocystis carinii. Biochim Biophys Acta 2001; 1515:177-188.
81. Zilberstein D, Liveanu B, Gepstein A. Tricyclic drugs reduce proton motive force in Leishmania donovani promastigotes. Biochem Pharmacol 1990; 39:935-940.
82. Cushion MT, Chen F, Kloepfer N. A cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents. Antimicrob Agents Chemother 1997; 41: 379-384.
83. Banerji S, Wakefield AE, Allen AG, Maskell DJ, Peters SE, Hopkin JM. The cloning and characterization of the arom gene of Pneumocystis carinii. J Gen Microbiol 1993; 139:2901-2914.
84. Chin K, Wyder MA, Kaneshiro ES. Glyphosate reduces organism viability and inhibits growth in vitro of Pneumocystis. J Eukaryot Microbiol 1999; 46: 139S-141S.
85. Hughes WT, Gray VL, Gutteridge WE, Latter VS, Pudney M. Efficacy of ahydroxy-napthoquinone, 566C80, in experimental parasitic infections of AIDS pneumonitis. Antimicrob Agents Chemother 1990; 34:225-228.
86. Gutteridge W. 566C80, An antimalarial hydroxynaphthoquinone with broad spectrum: experimental activity against opportunistic parasitic infections of AIDS patients. J Eukaryot Microbiol 1991; 38:141S-143S.
87. Dohn MN, Frame PT, Baughman RP, Lafon SW, Smulian AG, Caldwell P, Rogers MD. Open-label efficacy and safety trial of 42 days of 566C80 for Pneumocystis carinii pneumonia in AIDS patients. J Eukaryot Microbiol 1992; 38:220S-221S.
88. Chan C, Montaner J, Lefebvre E-A, Morey G, Dohn M, McIvor RA, Scott J, Marina R, Caldwell P. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis 1999; 180:369-376.
89. Cushion MT, Collins M, Hazra B, Kaneshiro ES. The effects of atovaquone and diospyrin-based drugs on the ATP content of Pneumocystis carinii f. sp carinii. Antimicrob Agents Chemother 2000; 44:713-719.
90. Kaneshiro ES, Sul D, Hazra B. Effects of atovaquone and diospyrin-based drugs on ubiquinone biosynthesis in Pneumocystis carinii. Antimicrob Agents Chemother 2000; 44:14-18.
91. Kaneshiro ES, Sul D, Basselin M, Kayser O. Pneumocystis carinii synthesizes four ubiquinone homologs: inhibition by atovaquone and bupravaquone but not by stigmatellin. J Eukaryot Microbiol 2001; 48:172S-173S.
92. Kaneshiro ES. Is cytochrome b gene mutations the only cause of atovaquone resistance in Pneumocystis?. Drug Resist Updates 2001; 5:322-329.
93. Kaneshiro ES, Cushion MT, Walzer PD, Jayasimhulu K. Analysis of Pneumocystis fatty acids. J Protozool 1989; 36:69S-72S.
94. Guo Z, Beach DH, Kaneshiro ES. Fatty acid composition of the major phospholipids of Pneumocystis carinii carinii: comparison with those in the lungs of normal and methylprednisolone-immununosuppressedrats. Infect Immun 1996; 64:1407-1412.
95. Racagni G, de Lema MG, Hernandez G, Machado-Domenech EE. Fetal bovine serum induces changes in fatty acid composition of Trypanosoma cruzi phosphoino-sitides. Can J Microbiol 1995; 41:951-954.
96. Ellis JE, Reilly MH, Kaneshiro ES. Identification of an epoxy fatty acid in Pneumocystis carinii lipids. J Eukaryot Microbiol 1994; 41:87S.
97. Chin K, Kaneshiro ES. The distribution and biosynthesis of cis-9,10-epoxyoctadeca-noic acid in Pneumocystis carinii. J Eukaryot Microbiol 1999; 46:123S-124S.
98. Tulloch AP. The oxygenated fatty acids of the oil of wheat stem rust uredospores. Can J Chem 1960; 38:204-207.
99. Guadiz G, Haidaris C, Maine GN, Simpson-Haidaris PJ. The carboxyl terminus of Pneumocystis carinii glycoprotein A encodes a functional glycosylphosphatidyli-nositol signal sequence. J Biol Chem 1998; 273:26202-26209.
100. Palmer RJ. Wakefield AE. Functional glycosylphosphatidylinositol anchor signal sequences in the Pneumocystis carinii PRT1 protease family. Am J Respir Cell Mol Biol 2001; 25:466-473.
101. De Stefano J, Cushion MT, Puvanesarajah V, Walzer PD. Analysis of Pneumocystis carinii cyst wall. II. Sugar composition. J Protozool 1990; 37:436-441.
102. Kaneshiro ES, Jayasimhulu J, De Stefano J. Lipid modification of Pneumocystis carinii major surface antigen. Third NIAID Workshop in Medical Mycology Series, Big Sky, MO, Sept 7-9, 1995.
103. Kernbaum S, Masliah U, Alcindor LG, Bouton C, Cristol D. Phospholipase activities of bronchoalveolar lavage fluid in rat Pneumocystis carinii pneumonia. Br J Exp Pathol 1983; 64:75-80.
104. Hoffman AGD, Lawrence MG, Ognibene FP, Suffredini AF, Lipschik GY, Kovacs JA, Masur H, Shelhamer JH. Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia. Chest 1992; 102:1730-1738.
105. Dichter JR, Lundgren JD, Nielsen TL, Jensen BN, Schattenkerk J, Benfield TL, Lawrence M, Shelhamer J. Pneumocystis carinii pneumonia in HIV-infected patients: effect of steroid therapy on surfactant level. Respir Med 1999; 93:373-378.
106. Chandra J, Amit Z, Baughman RP, Kleykamp B, Kaneshiro ES. Pneumocystis infection is correlated with a reduction in the total sterol content of human bron-choalveolar lavage fluid. J Eukaryot Microbiol 1999; 46:146S-148S.
107. Escamilla R, Prevost M-C, Hermant C, Caratero A, Cariven C, Krempf M. Surfactant analysis during Pneumocystis carinii pneumonia in HIV-infected patients. Chest 1992; 101:1558-1562.
108. Aliouat EM, Escamilla R, Cariven C, Vieu C, Mullet C, Dei-Cas E, Prevost MC. Surfactant changes during experimental pneumocystosis are related to Pneumocystis development. Eur Respir J 1998; 11:542-547.
109. Atochina EN, Beers MF, Scanlon ST, Preston AM, Beck JM. P. carinii induces selective alterations in component expression and biophysical activity of lung surfactant. Am J Physiol Lung Cell Mol Physiol 2000; 278:L599-L609.
110. Su TH, Viswanathan N, Kachel DL, Moxley MA, Longmore WJ, Martin WJ. Functional impairment of bronchoalveolar lavage phospholipids in early Pneumocystis carinii pneumonia in rats. J Lab Clin Med 1996; 127:263-271.
111. Rose RM, Catalano PJ, Koziel H, Furlong ST. Abnormal lipid composition of bronchoalveolar lavage fluid obtained from individuals with AIDS-related lung disease. Am J Respir Crit Care Med 1994; 149:332-338.
112. Wright TW, Notter RH, Wang Z, Harmsen AG, Gigliotti F. Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia. Infect Immun 2001; 69:758-764.
113. Gottschall JL, Walzer PD, Yoneda K. The morphologic changes of the rat type II pneumocytes induced by oxytetracycline. Lab Invest 1979; 41:5-12.
114. Rice WR, Singleton FM, Linke MJ, Walzer PD. Regulation of surfactant phosphatidylcholine secretion from alveolar type II cells during Pneumocystis carinii pneumonia in the rat. J Clin Invest 1993; 92:2778-2899.
115. Lipschik GY, Treml JF, Moore SD, Beers MF. Pneumocystis carinii glycoprotein A inhibits surfactant phospholipid secretion by rat alveolar type II cells. J Infect Dis 1998; 177:182-187.
116. Su TH, Natarajan V, Martin WJ. Pulmonary surfactant in Pneumocystis carinii pneumonia is associated with a marked increase in sphingomyelin. Am Rev Respir Dis 1992; 145:A246.